OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CWEB56

Charlotte's Web Holdings Inc

PharmaceuticalsVerified

Charlotte's Web Holdings Inc operates with a debt-to-equity ratio of 0.92 and a current ratio of 3.48, indicating a moderate liquidity position with sufficient short-term assets to cover liabilities. However, the company's operating cash flow is negative at -7.18 million USD, and free cash flow is also negative at -9.20 million USD, signaling potential challenges in generating positive cash from operations. Profitability metrics show a return on equity of -20.64% and a return on assets of -6.8%, both significantly below industry norms for pharmaceutical firms, which typically exhibit positive returns. The company reported a net loss of 9.63 million USD and an operating loss of 8.37 million USD, highlighting a lack of profitability. The company's revenue is concentrated in a single business segment focused on hemp-based pharmaceuticals and consumer products, with no disclosed geographic diversification. This concentration increases exposure to regulatory and market risks in the cannabis industry. Looking ahead, the company is projected to see a decline in revenue, with a negative outlook for the current fiscal year. Historical revenue data shows a decrease from 12.12 million USD in the latest period, and no significant growth drivers are currently evident. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could constrain its ability to fund operations without external financing. Recent filings and transcripts have not disclosed any major strategic shifts or new product launches. The company continues to focus on its core hemp-based product line, with no indication of diversification or expansion into new markets.

30-day price · CWEB-0.32 (-34.0%)
Low$0.62High$1.09Close$0.62As of10 May, 00:00 UTC
Profile
CompanyCharlotte's Web Holdings Inc
TickerCWEB.TO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Charlotte's Web Holdings Inc develops and commercializes hemp-based pharmaceutical and consumer products, targeting chronic pain, inflammation, and other medical conditions.

Classification. The company is classified in the Healthcare sector under Pharmaceuticals & Medical Research, with a confidence level of 0.92 based on verified market data.

Charlotte's Web Holdings Inc operates with a debt-to-equity ratio of 0.92 and a current ratio of 3.48, indicating a moderate liquidity position with sufficient short-term assets to cover liabilities. However, the company's operating cash flow is negative at -7.18 million USD, and free cash flow is also negative at -9.20 million USD, signaling potential challenges in generating positive cash from operations. Profitability metrics show a return on equity of -20.64% and a return on assets of -6.8%, both significantly below industry norms for pharmaceutical firms, which typically exhibit positive returns. The company reported a net loss of 9.63 million USD and an operating loss of 8.37 million USD, highlighting a lack of profitability. The company's revenue is concentrated in a single business segment focused on hemp-based pharmaceuticals and consumer products, with no disclosed geographic diversification. This concentration increases exposure to regulatory and market risks in the cannabis industry. Looking ahead, the company is projected to see a decline in revenue, with a negative outlook for the current fiscal year. Historical revenue data shows a decrease from 12.12 million USD in the latest period, and no significant growth drivers are currently evident. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could constrain its ability to fund operations without external financing. Recent filings and transcripts have not disclosed any major strategic shifts or new product launches. The company continues to focus on its core hemp-based product line, with no indication of diversification or expansion into new markets.
Key takeaways
  • The company has a negative return on equity and return on assets, indicating poor profitability.
  • Liquidity is moderate, with a current ratio of 3.48, but operating and free cash flows are negative.
  • Revenue is concentrated in a single business segment, increasing exposure to market and regulatory risks.
  • The company is projected to see a decline in revenue, with no significant growth drivers identified.
  • Liquidity risk is medium, and dilution risk is low, but the company's net cash position is negative after accounting for total debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$12.1M
Gross profit$6.9M
Operating income-$8.4M
Net income-$9.6M
R&D
SG&A
D&A
SBC
Operating cash flow-$7.2M
CapEx-$2.1M
Free cash flow-$9.2M
Total assets$141.8M
Total liabilities$95.1M
Total equity$46.7M
Cash & equivalents$38.5M
Long-term debt$42.7M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$96.1M-$147.1M-$137.7M-$131.6M
FY-3$74.1M-$52.5M-$59.3M-$52.1M
FY-2$63.2M-$40.6M-$23.8M-$21.6M
FY-1$49.7M-$32.0M-$29.8M-$29.4M
FY0$49.9M-$20.3M-$29.7M-$26.1M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$171.5M$130.4M$19.5M
FY-3$187.6M$77.5M$67.0M
FY-2$152.5M$55.6M$47.8M
FY-1$113.4M$27.1M$22.6M
FY0$75.3M-$2.0M$8.0M
PeriodOCFCapExFCFSBC
FY-4-$29.6M-$4.9M-$131.6M
FY-3-$5.3M-$265.0k-$52.1M
FY-2-$15.4M-$3.7M-$21.6M
FY-1-$21.3M-$3.9M-$29.4M
FY0-$14.1M-$549.0k-$26.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$12.1M-$8.4M-$9.6M-$9.2M
FQ-6$12.3M-$12.1M-$11.1M-$9.8M
FQ-5$12.6M-$6.0M-$5.8M-$3.6M
FQ-4$12.7M-$5.5M-$3.4M-$1.1M
FQ-3$12.3M-$5.3M-$6.2M-$4.3M
FQ-2$12.8M-$4.1M-$6.3M-$5.6M
FQ-1$11.5M-$5.3M-$5.8M-$4.1M
FQ0$13.3M-$5.6M-$11.4M-$9.6M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$141.8M$46.7M$38.5M
FQ-6$129.8M$35.8M$32.5M
FQ-5$119.6M$30.2M$24.6M
FQ-4$113.4M$27.1M$22.6M
FQ-3$108.0M$21.1M$19.4M
FQ-2$88.0M$14.9M$15.3M
FQ-1$81.6M$9.2M$9.8M
FQ0$75.3M-$2.0M$8.0M
PeriodOCFCapExFCFSBC
FQ-7-$7.2M-$2.1M-$9.2M
FQ-6-$11.9M-$3.3M-$9.8M
FQ-5-$19.5M-$3.6M-$3.6M
FQ-4-$21.3M-$3.9M-$1.1M
FQ-3-$2.8M-$521.0k-$4.3M
FQ-2-$6.8M-$652.0k-$5.6M
FQ-1-$12.2M-$650.0k-$4.1M
FQ0-$14.1M-$549.0k-$9.6M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$46.7M
Net cash-$4.2M
Current ratio3.5
Debt/Equity0.9
ROA-6.8%
ROE-20.6%
Cash conversion75.0%
CapEx/Revenue-17.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricCWEBActivity
Op margin-69.0%2.4% medp25 -91.8% · p75 12.5%below median
Net margin-79.5%1.2% medp25 -98.4% · p75 10.4%below median
Gross margin57.0%45.6% medp25 29.8% · p75 66.7%above median
CapEx / revenue-17.0%-5.2% medp25 -15.8% · p75 -1.7%bottom quartile
Debt / equity92.0%9.3% medp25 0.1% · p75 43.8%top quartile
Observations
IR observations
Last actual EPS-0.19 USD
Last actual revenue49,897,000 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 10:03 UTC#66eea1b3
Market quoteclose USD 0.62 · shares 0.16B diluted
no public URL
2026-05-10 10:03 UTC#0edb8c56
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 17:46 UTCJob: 1b0d3d93